CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing Post author: Post published:December 4, 2023 Post category:uncategorized CN Bio today announced its PhysioMimix® assay for Non-alcoholic steatohepatitis (NASH). You Might Also Like Psychological stress drives ovarian tumor metastasis through NR3C1 and NUPR1 July 10, 2025 Exercise prevents the incidence of dementia in older people with osteoarthritis October 5, 2023 Metabolic syndrome linked to higher risk of Parkinson’s disease August 20, 2025